Related Experiment Video
Updated: May 22, 2026

Heterotopic Renal Autotransplantation in a Porcine Model: A Step-by-Step Protocol
Published on: February 21, 2016
Proteinuria after kidney transplantation
Claudio Ponticelli1, Giorgio Graziani
1Division of Nephrology, Humanitas Scientific Institute, Rozzano, Milano, Italy. ponticelli.claudio@gmail.com
Abstract:
The prevalence of proteinuria at 1 year after renal transplantation ranges between 11% and 45% and is even higher in patients treated with inhibitors of the mammalian target of rapamycin (mTOR). Two main mechanisms can lead to proteinuria: an inadequate reabsorption of small proteins from proximal tubular cells damaged by ischemia-reperfusion injury, rejection, or toxic agents (tubular proteinuria) or an increased passage of albumin and/or protein with higher molecular weight (MW) because of a disruption of glomerular barrier caused by recurrent or de novo glomerulonephritis, transplant glomerulopathy, chronic rejection, or CNI toxicity (glomerular proteinuria). Proteinuric patients have worse patient and graft survival rates in comparison to non proteinuric patients. The amount of proteinuria is a reliable predictor of the allograft outcome. However, even microalbuminuria may be associated with a poor outcome. Treatment of proteinuria mainly rests on the management of the etiologic cause. Inhibitors of renin-angiotensin system (RAS) are useful in reversing microalbuminuria and can reduce proteinuria, but their efficacy in interfering with patient or graft survival is not demonstrated.
Insights
Proteinuria after kidney transplant, common in mTOR inhibitor users, predicts worse graft survival. Identifying the cause, whether tubular or glomerular, is key for managing transplant outcomes.
Area of Science:
- Nephrology
- Transplantation Immunology
- Renal Medicine
Background:
- Proteinuria is a significant complication following renal transplantation, affecting 11-45% of patients at one year.
- Prevalence is higher in patients treated with mammalian target of rapamycin (mTOR) inhibitors.
- Proteinuria is linked to poorer patient and graft survival rates post-transplant.
Purpose of the Study:
- To elucidate the mechanisms and implications of proteinuria in renal transplant recipients.
- To highlight the prognostic value of proteinuria for allograft outcomes.
- To review current treatment strategies for proteinuria in this population.
Main Methods:
- Review of existing literature on proteinuria post-renal transplantation.
- Categorization of proteinuria into tubular and glomerular mechanisms.
- Analysis of the relationship between proteinuria levels and patient/graft survival.
Main Results:
- Proteinuria arises from either impaired proximal tubular reabsorption or glomerular barrier dysfunction.
- Specific causes include ischemia-reperfusion, rejection, toxic agents, glomerulonephritis, and calcineurin inhibitor toxicity.
- The degree of proteinuria reliably predicts allograft outcome, with even microalbuminuria indicating a poor prognosis.
Conclusions:
- Management of proteinuria hinges on addressing the underlying etiology.
- Renin-angiotensin system (RAS) inhibitors can mitigate microalbuminuria and reduce proteinuria.
- The impact of RAS inhibitors on overall patient and graft survival remains unproven.
Related Concept Videos
Kidney Transplant II: Surgical Procedure
Kidney Transplant III: Nursing Management
Kidney Transplant I: Introduction
Nephrotic Syndrome II : Assessment and Medical Management
Acute Kidney Injury III: Clinical Manifestations
Nephrotic Syndrome I : Introduction

